一種新型系統被設計用于將內科醫生專用藥物以及其它治療藥物直接給予腎功能不全患者的腎動脈之中，這些患者將從靶向腎臟治療(TRT)中獲益，包括那些充血性心衰的患者。這套系統已經獲得了美國食品藥品管理局的許可。

Benephit Delta系統是系統性靜脈灌注給藥系統標準給藥方法的替代選擇，用于治療腎功能不全相關的心血管疾病、腎功能衰竭、以及充血性心衰。這套系統的早期版本局限在介入實驗室中應用，將單個導管放入患者腹股溝股動脈入口處，進行介入手術進行靶向腎臟治療。

Benephit Delta系統外觀簡練、靈活性增加、長度更長，從而能夠進入諸如上肢這樣的動脈位點。系統設計當患者接受治療的時候具有更大機動性，當離開實驗室的時候具有更好的舒適度。患者將從這種靶向腎臟治療方法中獲益，包括出現腎功能衰竭的慢性心衰患者以及急性腎功能衰竭患者。

Scripps診所心血管科介入心臟病學主任Paul Teirstein醫生評論說：“除了心-腎綜合征的充血性心衰患者之外，Delta系統還能夠用于治療在重癥監護室、手術中間或之后發生急性腎功能衰竭的患者。”

Benephit Delta系統是由FlowMedica公司研制開發成功的。

Infusion System for Kidney Patients
 
A new system is designed for the administration of physician-specified medications and other therapeutic agents directly into the renal arteries of patients with kidney dysfunction who may benefit from targeted renal therapy (TRT), including those with congestive heart failure. The system has been cleared by the U.S. Food and Drug Administration (FDA).

The Benephit Delta system is an alternative to the standard delivery method of systemic intravenous (IV) infusion of medications to treat kidney dysfunction related to cardiovascular disease, kidney failure, and congestive heart failure (CHF). An earlier version of the system was limited to use in the interventional laboratory, where a single catheter is placed in a femoral artery access site in the patient’s groin enabling interventional procedures to take place concurrently with TRT.

The reduced profile, increased flexibility, and longer lengths of the Benephit Delta system allow for access through arterial sites such as the arm. The system is designed to allow greater patient mobility and ease in providing therapy once the patient leaves the interventional laboratory. Patients who may benefit from this approach to TRT include CHF patients who develop kidney dysfunction and patients with acute renal failure.

“In addition to congestive heart failure patients who develop cardiorenal syndrome, the Delta system might also be used to provide therapy to patients who develop acute kidney failure while in the intensive care unit, during or after surgery,” commented Paul Teirstein, M.D., director of interventional cardiology, Division of Cardiovascular Diseases, Scripps Clinic (La Jolla, CA, USA).

The Benephit Delta system was developed by FlowMedica (Fremont, CA, USA).